Accor a signé un accord avec Blackstone pour lui céder sa participation dans Essendi|Sealed Air élargit de nouveau le price talk et renforce ses covenants face aux réticences des investisseurs|Grifols : l’upsize des nouveaux TLB 2033 permettra de refinancer les obligations secured 2027|
Webuild: Termination of Trojena project but positive momentum should continue|Emeria : une situation inchangée après le call des résultats 2025|Asmodee acquiert ATM Gaming pour 180 m EUR|Kantar : meilleures perspectives en 2026, Bain envisage une sortie dans donner d’horizon précis|
NEWS SUMMARY: ELECTRICITY SECTOR, GRIFOLS, INDRA, MERLÍN PROPERTIES, VIDRALA. Markets continue to rally European stock markets continued to recover, underpinned by the US proposal for a ceasefire in the Middle East, although the gains were reeled in slightly after Iran rejected the proposal. In the STOXX 600, all the sectors were in green, with Basic Materials and Financial Services leading the way, whereas defensive sectors like Household Goods and Telecoms rose the least. On the macro side, ...
A director at DiaSorin S.p.A. bought 9,211 shares at 54.200EUR and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
Grifols Shares Results From its Chronos Platform Identifying Early Molecular Changes Associated with Parkinson’s Disease Chronos‑PD shows that biological changes associated with Parkinson’s disease (PD) can emerge up to 12 years before clinical diagnosisUncovered reproducible early molecular signals and distinct molecular patterns in PD, supporting future efforts in patient stratification and precision medicine researchChronos is part of a broad Grifols program to find early disease biomarkers leveraging more than 100 million proprietary plasma samples connected to real-world data on thousa...
INEOS Quattro: conference call comments|NIH: improvement in certain indicators in H2, but still little visibility on M&A|Ardagh Group surprises with strong increase in glass EBITDA in Q4|Clariane : Satisfactory 2025 results thanks to strong recovery in H2 25 and B2/B+ ratings assigned by Moody’s and S&P|
INEOS Quattro: conference call comments|NIH : amélioration de certains indicateurs au S2 mais toujours peu de visibilité sur le M&A|Ardagh Group surprend avec une forte hausse de l’EBITDA verre au T4|Clariane : Résultats 2025 satisfaisants grâce à un bon rattrapage au 2nd semestre et ratings B2/B+ attribués par Moody’s et S&P|
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.